{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:45:31Z","timestamp":1772714731891,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009310","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T00:00:00Z","timestamp":1455580800000}}],"reference-count":96,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009310.pub2","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T10:43:52Z","timestamp":1455619432000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes"],"prefix":"10.1002","volume":"2016","author":[{"given":"Franz","family":"Hutzschenreuter","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Anton","family":"Kreuzer","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,2,16]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD009310.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00277-005-0044-6","article-title":"Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study","volume":"85","author":"Balleari","year":"2006","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0002|cit2","first-page":"196a","article-title":"Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS)","volume":"Suppl","author":"Greenberg","year":"1993","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009310.pub2-BIB0003|cit3","first-page":"A28","article-title":"Long term treatment of intermediate risk myelodysplastic syndromes with rhG-CSF and rhEPO: interim report of an ongoing randomized phase III trial","volume":"73","author":"Mantovani","year":"1996","journal-title":"Annals of Hematology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD009310.pub2-BIB0004|cit4","first-page":"338a","article-title":"Randomized Phase II study on the value of G-CSF (Filgrastim) in combination with standard induction chemotherapy in myelodysplastic syndromes (MDS)","volume":"86","author":"Ossenkoppele","year":"1995","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD009310.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.leu.2401478","article-title":"A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group","volume":"13","author":"Ossenkoppele","year":"1999","journal-title":"Leukemia"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD009310.pub2-BIB0006|cit6","first-page":"630","article-title":"A randomized study of granulocyte-colony stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: A final report from the HOVON Co-operative Group","volume":"92","author":"Ossenkoppele","year":"1998","journal-title":"Blood"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD009310.pub2-BIB0007|cit7","first-page":"633a","article-title":"Evaluation of lenograstim in patients with poor prognosis refractory anaemia with excess of blasts (RAEB) treated with ARA-C(3mg\/m2 x 2)","volume":"92","author":"Taieb","year":"1998","journal-title":"Blood"},{"issue":"Suppl","key":"10.1002\/14651858.CD009310.pub2-BIB0008|cit8","first-page":"A51","article-title":"Treatment of high-risk myelodysplastic syndromes with sequential intermediate dose cytosine-arabinoside and mitoxantrone (S-HAM) with or without GM-CSF: a prospective double blinded randomized study","volume":"67","author":"Hiddemann","year":"1993","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0009|cit9","first-page":"A109","article-title":"Intensive therapy of high risk myelodysplastic syndromes with sequential intermediate dose cytosine arabinoside and mitoxantrone with or without GM-CSF","volume":"70 Suppl 1","author":"Hiddemann","year":"1995","journal-title":"Annals of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD009310.pub2-BIB0010|cit10","first-page":"369","article-title":"Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside\/mitoxantrone chemotherapy with or without granulocyte\/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes","volume":"125","author":"Verbeek","year":"1999","journal-title":"Research & Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009310.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002770050285","article-title":"S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes","volume":"74","author":"Verbeek","year":"1997","journal-title":"Annals of Hematology"},{"issue":"10","key":"10.1002\/14651858.CD009310.pub2-BIB0012|cit12","first-page":"580a","article-title":"Randomized-3 armed phase III study of interleukin 3 (IL-3) or granulocyte\/macrophage colony-stimulating factor (GM-CSF) as an adjuvant to low doses of cytosine arabinoside (LD-AraC) for the treatment of high-risk myelodysplastic syndromes (HR-MDS)","volume":"88","author":"Gerhartz","year":"1996","journal-title":"Blood"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD009310.pub2-BIB0013|cit13","first-page":"85a","article-title":"Randomized 3 arm phase III study of interleukin 3 (IL-3) or granulocyte\/macrophage colony-stimulating factor (GM-CSF) as an adjuvant to low doses of cytosine arabinoside (LD-AraC) for the treatment of high-risk myelodysplastic syndrome (HR-MDS)","volume":"90","author":"Gerhartz","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD009310.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.leu.2400641","article-title":"Clonality analysis as a tool to study the biology and response to therapy in myelodysplastic syndromes","volume":"11","author":"Schmetzer","year":"1997","journal-title":"Leukemia"},{"issue":"11","key":"10.1002\/14651858.CD009310.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/sj.leu.2403934","article-title":"Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte\/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group","volume":"19","author":"Zwierzina","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"10.1002\/14651858.CD009310.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2141.1998.00816.x","article-title":"Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS","volume":"102","author":"Bernasconi","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Bowen D Hyslop A Keenan N Groves M Culligan D Johnson P Prediction of response to recombinant erythropoietin plus granulocyte-colony stimulating factor following a single subcutaneous bolus in patients with myelodysplastic syndromes; a randomised placebo controlled study Blood 2004 402a","DOI":"10.1182\/blood.V104.11.1435.1435"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0018|cit18","first-page":"709","article-title":"Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia","volume":"91","author":"Bowen","year":"2006","journal-title":"Haematologica"},{"issue":"8","key":"10.1002\/14651858.CD009310.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","article-title":"Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +\/- all-trans retinoic acid +\/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"93","author":"Estey","year":"1999","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0027|cit20","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/0959-8049(93)90873-E","article-title":"Randomized phase II study LD-ARAC plus rhGM-CSF in advanced myelodysplasia [abstract no: 249]","volume":"29A","author":"Gerhartz","year":"1993","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0020|cit21","first-page":"255","article-title":"Randomized phase II trial of low-dose ARA-C and human recombinant GM-CSF in refractory anemia with excess of blasts","volume":"59","author":"Gerhartz","year":"1989","journal-title":"Blut"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0021|cit22","first-page":"16","article-title":"A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group","volume":"8","author":"Gerhartz","year":"1994","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0024|cit23","first-page":"274a","article-title":"Randomized phase II study with GM-CSF and low-dose Ara-C in patients with \"high risk\" myelodysplastic syndromes (MDS)","volume":"76","author":"Gerhartz","year":"1990","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0022|cit24","first-page":"A95","article-title":"Randomized phase II study with GM-CSF and low-dose ARAC in patients with \"high risk\" myelodysplastic syndromes (MDS)","volume":"62 Suppl 1","author":"Gerhartz","year":"1991","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0023|cit25","doi-asserted-by":"crossref","first-page":"Suppl","DOI":"10.1007\/BF01705030","article-title":"Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group","volume":"20","author":"Gerhartz","year":"1992","journal-title":"Infection"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0025|cit26","first-page":"Suppl","article-title":"Low-dose Ara-C plus granulocyte\/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group","volume":"4","author":"Gerhartz","year":"1989","journal-title":"Bone Marrow Transplantation"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0026|cit27","first-page":"21","article-title":"Use of rhGM-CSF or IL-3 as an adjunct to low-dose ARA-C in the treatment of \"high-risk\" myelodysplasia","volume":"16","author":"Gerhartz","year":"1993","journal-title":"Onkologie"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0028|cit28","first-page":"15","article-title":"A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes","volume":"84","author":"Gotlib","year":"2009","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD009310.pub2-BIB0030|cit30","first-page":"615a","article-title":"GM-CSF in combination with chemotherapy does not improve the remission rate in acute leukaemia after myelodysplastic syndromes - A randomized study","volume":"92","author":"Bernell","year":"1998","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD009310.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2403035","article-title":"No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease","volume":"17","author":"Hast","year":"2003","journal-title":"Leukemia"},{"issue":"11","key":"10.1002\/14651858.CD009310.pub2-BIB0032|cit32","first-page":"148a","article-title":"Randomized study comparing chemotherapy plus GM-CSF in high-risk MDS and AML following MDS (MDS-AML)","volume":"96","author":"Ohm","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"Suppl","DOI":"10.1016\/S0145-2126(98)00035-6","article-title":"Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients. [Review] [16 refs]","volume":"22","author":"Miller","year":"1998","journal-title":"Leukemia Research"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD009310.pub2-BIB0034|cit34","first-page":"332a","article-title":"The efficacy of GM-CSF in the treatment of myelodysplastic syndrome and aplastic anemia","volume":"74","author":"Schuster","year":"1989","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0035|cit35","first-page":"205, Abstract","article-title":"Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) versus observation in patients (PTS) with myelodysplastic syndrome (MDS) or aplastic anemia (AA) [abstract]","volume":"9","author":"Schuster","year":"1990","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0036|cit36","unstructured":"Schuster MW Thompson JA Larson R Allen SL O'Laughlin R Israel R Randomized trial of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) versus observation in patients (PTS) with myelodysplastic syndrome (MDS) or aplastic anemia (AA) [abstract] Journal of Cancer Research & Clinical Oncology 1990 1079"},{"issue":"9","key":"10.1002\/14651858.CD009310.pub2-BIB0037|cit37","first-page":"957","article-title":"GM-CSF treatment of myelodysplastic syndromes: personal experience and preliminary results of a randomized international study","volume":"39","author":"Coiffier","year":"1992","journal-title":"Pathologie Biologie"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD009310.pub2-BIB0038|cit38","first-page":"318a","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): results of a multi-center randomized controlled trial","volume":"76","author":"Schuster","year":"1990","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD009310.pub2-BIB0039|cit39","first-page":"338a","article-title":"Randomized Phase II study of recombinant granulocyte macrophage-colony stimulating factor (rGM-CSF) in patients with neutropenia secondary to myelodysplastic syndrome (MDS)","volume":"86","author":"Schuster","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood-2004-04-1334","article-title":"Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges","volume":"104","author":"Stasi","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0041|cit41","first-page":"147a","article-title":"Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor","volume":"96","author":"Terpos","year":"2000","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD009310.pub2-BIB0042|cit42","first-page":"337a, Abstract","article-title":"The use of GM-CSF \u00b1 r-HuEPO for the treatment of cytopenias associated with myelodysplastic syndrome (MDS)","volume":"86","author":"Thompson","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/10428199209058663","article-title":"GM-CSF and IL-3 in myelodysplastic syndromes at low risk of developing acute leukemia (MDS-LR) [abstract]","volume":"7 Suppl 2","author":"Willemze","year":"1992","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0044|cit44","unstructured":"Erythropoietin\u00a0and\u00a0G\u00adCSF\u00a0for\u00a0low\u00adrisk\u00a0MDS (NCT00234143) Ongoing study October 2004"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0045|cit45","unstructured":"Comparison study of standard care against combination of growth factors agents for low-risk MDS (NCT01196715) Ongoing study November 2010"},{"issue":"25","key":"10.1002\/14651858.CD009310.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1182\/blood-2010-01-234120","article-title":"G-CSF and its receptor in myeloid malignancy","volume":"115","author":"Beekman","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2141.1998.00816.x","article-title":"Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS","volume":"102","author":"Bernasconi","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD009310.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04450.x","article-title":"Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review","volume":"122","author":"Bohlius","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD009310.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.03907.x","article-title":"Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes","volume":"120","author":"Bowen","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ctrv.2010.05.006","article-title":"5-Azacytidine in myelodysplastic syndromes: A clinical practice guideline","volume":"37","author":"Buckstein","year":"2011","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0052|cit52","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Deeks","year":"2011"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.leu.2401442","article-title":"Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin","volume":"13","author":"Economopoulos","year":"1999","journal-title":"Leukemia"},{"issue":"4","key":"10.1002\/14651858.CD009310.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1365-2141.1998.01085.x","article-title":"A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes","volume":"103","author":"Ferrini","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/annonc\/mdq179","article-title":"Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21 Suppl 5","author":"Fey","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Gerhartz HH Marcus R Delmer A Zwierzina H de Witte T Jacobs A Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group Infection 1992 116 23","DOI":"10.1007\/BF01705030"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0057|cit57","unstructured":"Gerhartz HH Marcus R Delmer A Zwierzina H Suciu S Dardenne M A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group Leukemia 1994 16 23"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00277-010-1015-0","article-title":"Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group","volume":"89","author":"Gotze","year":"2010","journal-title":"Annals of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD009310.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ajh.2830440403","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes","volume":"44","author":"Hansen","year":"1993","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD009310.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies","volume":"89","author":"Hellstrom-Lindberg","year":"1995","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD009310.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","article-title":"Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model","volume":"99","author":"Hellstrom-Lindberg","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD009310.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","article-title":"Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients","volume":"92","author":"Hellstrom-Lindberg","year":"1998","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0064|cit64","doi-asserted-by":"crossref","unstructured":"Hellstr\u00f6m-Lindberg E Gulbrandsen N Lindberg G Ahlgren T Dahl IM Dybedal I Scandinavian MDS Group A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life British Journal of Haematology 2003 1037 46","DOI":"10.1046\/j.1365-2141.2003.04153.x"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0065|cit65","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0066|cit66","article-title":"Chapter 7: Selecting studies and collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0067|cit67","article-title":"Chapter 16: Special topics in statistics","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"issue":"21","key":"10.1002\/14651858.CD009310.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"Jadersten","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0069|cit69","article-title":"Chapter 6: Searching for studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Lefebvre","year":"2011"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJM199207023270106","article-title":"Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1)","volume":"327","author":"Lieschke","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009310.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood.V84.6.1737.1737","article-title":"Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization","volume":"84","author":"Lieschke","year":"1994","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2141.2000.02016.x","article-title":"Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin","volume":"109","author":"Mantovani","year":"2000","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD009310.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD009310.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/cncr.24090","article-title":"An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach","volume":"115","author":"Mundle","year":"2009","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0075|cit75","unstructured":"Greenberg PL Attar E Battiwalla M Bennett JM Bloomfield CD DeCastro CM Myelodysplastic syndromes. NCCN clinical practice guidlines in oncology.V.1.2012 www.nccn.org\/professionals\/physician_gls\/PDF\/mds.pdf"},{"issue":"10","key":"10.1002\/14651858.CD009310.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076","article-title":"Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy","volume":"87","author":"Negrin","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0077|cit77","article-title":"Chapter 5: Defining the review question and developing criteria for including studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"O'Connor","year":"2011"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Ossenkoppele GJ van der Holt B Verhoef GE Daenen SM Verdonck LF Sonneveld P A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group Leukemia 1999 1207 13","DOI":"10.1038\/sj.leu.2401478"},{"issue":"2","key":"10.1002\/14651858.CD009310.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1002\/14651858.CD009310.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009310.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0268-960X(92)90007-D","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation","volume":"6","author":"Rapoport","year":"1992","journal-title":"Blood Reviews"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0082|cit82","unstructured":"Cochrane Review Manager (RevMan) Version 5.3 2014"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.leukres.2010.01.018","article-title":"Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines","volume":"34","author":"Santini","year":"2010","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0084|cit84","unstructured":"Schuster MW Thompson JA Larson R Coiffier V Bennett J Dugan M Randomized phase II study of recombinant granulocyte macrophage-colony stimulating factor (rGM-CSF) in patients with neutropenia secondary to myelodysplastic syndrome (MDS) Blood, Abstract 1341 1995 338a"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0085|cit85","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011"},{"issue":"12","key":"10.1002\/14651858.CD009310.pub2-BIB0086|cit86","first-page":"1344","article-title":"Management of myelodysplastic syndromes: 2008 update","volume":"22","author":"Scott","year":"2008","journal-title":"Oncology (Williston Park, N.Y.)"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0087|cit87","unstructured":"Altekruse SF Kosary CL Krapcho M Neyman N Aminou R Waldron W SEER Cancer Statistics Review , 1975-2007, National Cancer Institute. Bethesda, MD http:\/\/seer.cancer.gov\/csr\/1975_2007\/, based on November 2009 SEER data submission, posted to the SEER website 2010"},{"issue":"19","key":"10.1002\/14651858.CD009310.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009310.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4065\/81.1.104","article-title":"The myelodysplastic syndromes: diagnosis and treatment","volume":"81","author":"Steensma","year":"2006","journal-title":"Mayo Clinic proceedings. Mayo Clinic"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0090|cit90","article-title":"Chapter 10: Addressing reporting biases","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sterne","year":"2011"},{"issue":"19","key":"10.1002\/14651858.CD009310.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0093|cit93","first-page":"18","article-title":"Introduction and overview of the classification of myeloid neoplasms","volume-title":"\u00a0WHO classification of tumors of hematopoietic and lymphoid tissues","author":"Vardiman","year":"2008"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Verbeek W W\u00f6rmann B Koch P Aul C Hinrichs HF Balleisen L Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside\/mitoxantrone chemotherapy with or without granulocyte\/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes Journal of Cancer Research and Clinical Oncology 1999 369 74","DOI":"10.1007\/s004320050288"},{"issue":"6695","key":"10.1002\/14651858.CD009310.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.299.6695.375","article-title":"Pyogenic abscesses in the myelodysplastic syndrome","volume":"299","author":"Williamson","year":"1989","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009310.pub2-BIB0096|cit96","doi-asserted-by":"crossref","unstructured":"Zwierzina H Suciu S Loeffler-Ragg J Neuwirtova R Fenaux P Beksac M Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte\/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group Leukemia 2005 1929 33","DOI":"10.1038\/sj.leu.2403934"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009310.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T09:34:40Z","timestamp":1691400880000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009310.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,16]]},"references-count":96,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009310.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,16]]}}}